Author

Daryl DeKarske

Observed names: D. DeKarske, Daryl Dekarske, DeKarske, Daryl

Institution: Acadia Pharmaceuticals (United States)

Observed institution: Acadia Pharmaceuticals (United States)

ORCID: 0000-0003-2228-1328

Observed ORCID: 0000-0003-2228-1328

OpenAlex ID: A5072536531

An Open-Label, 8-Week Study of Safety and Efficacy of Pimavanserin Treatment in Adults with Parkinson’s Disease and Depression

2020 · Daryl DeKarske, Gustavo Alva, et al. · Journal of Parkinson s Disease · 24

A Phase 1, Open-Label Study to Evaluate the Effects of Food and Evening Dosing on the Pharmacokinetics of Oral Trofinetide in Healthy Adult Subjects

2022 · Mona Darwish, James M. Youakim, et al. · Clinical Drug Investigation · 21

Pimavanserin Exposure-Response Analyses in Patients With Schizophrenia: Results From the Phase 2 ADVANCE Study

2022 · Mona Darwish, Dragana Bugarski-Kirola, et al. · Journal of Clinical Psychopharmacology · 9

The effects of treatment with pimavanserin on activities of daily living in patients with Parkinson’s disease psychosis: a 16-week, single-arm, open-label study

2024 · Virgilio G. H. Evidente, Daryl DeKarske, et al. · Therapeutic Advances in Neurological Disorders · 5

Population Pharmacokinetic Modeling and Stochastic Simulations to Support Pediatric Dose Selection of Pimavanserin

2023 · Mona Darwish, Dragana Bugarski‐Kirola, et al. · The Journal of Clinical Pharmacology · 4

Palatability and Swallowability of Pimavanserin When Mixed with Selected Food Vehicles: An Exploratory Open-Label Crossover Study

2021 · Mark Forman, Alex Kouassi, et al. · Geriatrics · 4

Adherence to Background Antipsychotic and Pimavanserin in Patients with Schizophrenia: Post Hoc Analyses from the ENHANCE and ADVANCE Studies

2024 · Dragana Bugarski-Kirola, Brandon Abbs, et al. · Patient Preference and Adherence · 3

Exposure–response Modeling From the CLARITY Trial of Pimavanserin for Adjunctive Treatment of Major Depressive Disorder

2023 · Mona Darwish, Bryan Dirks, et al. · Clinical Pharmacology in Drug Development · 1

P.0775 Adherence to background antipsychotic and pimavanserin in patients with schizophrenia: post hoc analyses from the ENHANCE and ADVANCE trials

2021 · D. Bugarski-Kirola, B. Abbs, et al. · European Neuropsychopharmacology · 1

A 16-Week Open-Label Study of the Effects of Treatment With Pimavanserin on Activities of Daily Living in Subjects With Parkinson’s Disease Psychosis

2023 · Virgilio G. H. Evidente, Daryl DeKarske, et al. · CNS Spectrums

P.0779 Relationship between pimavanserin exposure and QTc interval in patients with schizophrenia: modelling analysis from randomised, double-blind, placebo-controlled studies

2021 · M. Darwish, D. Bugarski-Kirola, et al. · European Neuropsychopharmacology

Impact of concomitant acetylcholinesterase inhibitor use on the pharmacokinetic profile of pimavanserin in patients with dementia‐related psychosis: Modeling data from the phase 3 HARMONY study

2021 · Mona Darwish, David Jaworowicz, et al. · Alzheimer s & Dementia

Pimavanserin for Treatment of Comorbid Depression in Patients With Parkinson’s Disease (4516)

2020 · Michael Guskey, Gustavo Alva, et al. · Neurology

158 Open-label Study of Pimavanserin Patients with Comorbid Parkinson’s Disease and Depression

2020 · Michael T. Guskey, Gustavo Alva, et al. · CNS Spectrums

Works count: 22

Citation count: 72

H-index: 4

I10-index: 2